Singular Genomics Systems, Inc. (NASDAQ:OMIC) CEO Sells $15,672.25 in Stock

Singular Genomics Systems, Inc. (NASDAQ:OMIC) CEO Andrew Spaventa sold 695 shares of the stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $22.55, for a total value of $15,672.25. Following the transaction, the chief executive officer now owns 1,537 shares in the company, valued at $34,659.35. The trade was a 31.14 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Andrew Spaventa also recently made the following trade(s):

• On Sunday, September 15th, Andrew Spaventa sold 175 shares of Singular Genomics Systems stock. The shares were sold at an average price of $12.38, for a total transaction of $2,166.50.

Singular Genomics Systems Trading Down 3.7 %

NASDAQ:OMIC opened at $21.90 on Friday. Singular Genomics Systems, Inc. has a 12 month low of $5.34 and a 12 month high of $23.41. The company has a current ratio of 7.37, a quick ratio of 8.04 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $55.01 million, a price-to-earnings ratio of -0.62 and a beta of 1.51. The firm has a fifty day simple moving average of $15.64 and a two-hundred day simple moving average of $11.40.

Singular Genomics Systems (NASDAQ:OMIC) last issued its earnings results on Tuesday, November 12th. The company reported ($6.72) EPS for the quarter, beating the consensus estimate of ($8.05) by $1.33. Singular Genomics Systems had a negative return on equity of 57.87% and a negative net margin of 3,237.89%. The company had revenue of $0.41 million during the quarter, compared to the consensus estimate of $0.74 million.

Institutional Investors Weigh In On Singular Genomics Systems

A hedge fund recently raised its stake in Singular Genomics Systems stock. Geode Capital Management LLC boosted its holdings in Singular Genomics Systems, Inc. (NASDAQ:OMIC) by 7.1% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 17,962 shares of the company’s stock after purchasing an additional 1,193 shares during the quarter. Geode Capital Management LLC owned about 0.72% of Singular Genomics Systems worth $282,000 at the end of the most recent quarter. 65.80% of the stock is owned by institutional investors.

Singular Genomics Systems Company Profile

Singular Genomics Systems, Inc, a life science technology company, develops next generation sequencing and multiomics technology for researchers and clinicians to advance science and medicine. The company is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables for applications comprising single cell gene expression and proteomics, in situ RNA sequencing, and spatial RNA and proteomics applications for tissue.